ATR Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Purpose: Mutations in the DNA damage response gene ATR (exon 10 A10 mononucleotide repeat) have been previously described in endometrial and other cancers with defective DNA mismatch repair. In vitro studies showed that endometrial cancer cell lines with A10 repeat tract truncating mutations have a failure in the ATR-dependent DNA damage response. Cell lines carrying A10 mutations fail to trigger Chk1 activation in response to ionizing radiation and topoisomerase inhibitors. We sought to determine the frequency and clinicopathologic significance of ATR mutations in patients with endometrioid endometrial cancer. Patients and Methods: The ATR exon 10 A10 repeat was analyzed by direct sequencing in 141 tumors with microsatellite instability (MSI-positive) and 107 microsatellite stable (MSI-negative) tumors. The relationships between mutations and clinicopathologic variables, including overall and disease-free survival, were assessed using contingency table tests and Cox proportional hazard models. Results: ATR mutations were identified in 12 cases (4.8%; three cases with insertions and nine cases with deletions). Mutations occurred exclusively in MSI-positive tumors (P = .02), with an overall mutation rate of 8.5%. Mutation was not associated with age, race, surgical stage, International Federation of Gynecology and Obstetrics grade, or adjuvant treatment. Multivariate analyses revealed a significant association with reduced overall survival (hazard ratio [HR] = 3.88; 95% CI, 1.64 to 9.18; P = .002) and disease-free survival (HR = 4.29; 95% CI, 1.48 to 12.45; P = .007). Conclusion: Truncating ATR mutations in endometrial cancers are associated with biologic aggressiveness as evidenced by reduced disease-free and overall survival. Knowledge of ATR mutation status may hold promise for individualized treatment and targeted therapies in patients with endometrial cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2
Shieh, S.-Y., Ikeda, M., Taya, Y., & Prives, C. (1997) · Cell · doi:10.1016/s0092-8674(00)80416-x · Cited by 2,100 · cited 2×
“Phosphorylation at Ser-15 after DNA damage leads to reduced interaction of p53 with its negative regulator.(16-18) However, Ser-15 phosphorylation and p53 accumulation have been demonstrated in ataxia-telangiectasia cell lines (deficient in ATM), suggesting that ATM is not the only protein responsible for p53 modulati…”
BackgroundActivation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Enhanced Phosphorylation of p53 by ATM in Response to DNA Damage
Banin, S., Moyal, L., Shieh, S.-Y., Taya, Y., Anderson, C. W., Chessa, L., Smorodinsky, N. I., Prives, C., Reiss, Y., Shiloh, Y., et al. (1998) · Science · doi:10.1126/science.281.5383.1674 · Cited by 1,797
Liu, Q., Guntuku, S., Cui, X.-S., Matsuoka, S., Cortez, D., Tamai, K., Luo, G., Carattini-Rivera, S., DeMayo, F., Bradley, A., et al. (2000) · Genes & Development · doi:10.1101/gad.14.12.1448 · Cited by 1,625 · cited 1×
“ATR preferentially phosphorylates and activates the checkpoint kinase Chk1 resulting in G2 arrest in response to ionizing radiation, topoisomerase inhibitors, and cytotoxic methylation events.(23-27) Modulation of ATM/ATR functions may be an attractive intervention for cancer radiotherapy and chemotherapy.”
BackgroundA role for ATR in the DNA damage-induced phosphorylation of p53
Tibbetts, R. S., Brumbaugh, K. M., Williams, J. M., Sarkaria, J. N., Cliby, W. A., Shieh, S.-Y., Taya, Y., Prives, C., & Abraham, R. T. (1999) · Genes & Development · doi:10.1101/gad.13.2.152 · Cited by 1,046 · cited 1×
“ATR phosphorylates p53 at both Ser-15 and Ser-37 in vitro.(17-22) ATR preferentially phosphorylates and activates the checkpoint kinase Chk1 resulting in G2 arrest in response to ionizing radiation, topoisomerase inhibitors, and cytotoxic methylation events.”
BackgroundATR disruption leads to chromosomal fragmentation and early embryonic lethality
Brown, E. J., & Baltimore, D. (2000) · Genes & Development · doi:10.1101/gad.14.4.397 · Cited by 951 · cited 1×
“Biallelic loss is incompatible with life, as seen by the lethality of ATR deletions in early developmental stages.(29) However, Lewis et al(8) have demonstrated that monoallelic frameshift mutation is sufficient to affect downstream ATR effectors, suggesting dominant negative effects.”
BackgroundDNA damage induces phosphorylation of the amino terminus of p53
Siliciano, J. D., Canman, C. E., Taya, Y., Sakaguchi, K., Appella, E., & Kastan, M. B. (1997) · Genes & Development · doi:10.1101/gad.11.24.3471 · Cited by 818 · cited 2×
“ATR phosphorylates p53 at both Ser-15 and Ser-37 in vitro.(17-22) ATR preferentially phosphorylates and activates the checkpoint kinase Chk1 resulting in G2 arrest in response to ionizing radiation, topoisomerase inhibitors, and cytotoxic methylation events.”
BackgroundATR Kinase Activation Mediated by MutSα and MutLα in Response to Cytotoxic O6-Methylguanine Adducts
Yoshioka, K.-I., Yoshioka, Y., & Hsieh, P. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.04.023 · Cited by 288
S Phase and G2 Arrests Induced by Topoisomerase I Poisons Are Dependent on ATR Kinase Function
Cliby, W. A., Lewis, K. A., Lilly, K. K., & Kaufmann, S. H. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m106287200 · Cited by 205 · cited 1×
“ATR preferentially phosphorylates and activates the checkpoint kinase Chk1 resulting in G2 arrest in response to ionizing radiation, topoisomerase inhibitors, and cytotoxic methylation events.(23-27) Modulation of ATM/ATR functions may be an attractive intervention for cancer radiotherapy and chemotherapy.”
Background
Cited by
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
(2010) · Advances in Cancer Research · doi:10.1016/b978-0-12-380888-2.00003-0 · Cited by 1,276
Walker, B. A., Boyle, E. M., Wardell, C. P., Murison, A., Begum, D. B., Dahir, N. M., Proszek, P. Z., Johnson, D. C., Kaiser, M. F., Melchor, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.1503 · Cited by 567
Sorensen, C. S., & Syljuasen, R. G. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr697 · Cited by 318
ATR signalling: more than meeting at the fork
Nam, E. A., & Cortez, D. (2011) · Biochemical Journal · doi:10.1042/bj20102162 · Cited by 316
Molecular Genetics of Endometrial Carcinoma
Bell, D. W., & Ellenson, L. H. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020117-043609 · Cited by 304
Metadata
- Authors
- Zighelboim, I., Schmidt, A. P., Gao, F., Thaker, P. H., Powell, M. A., Rader, J. S., Gibb, R. K., Mutch, D. G., & Goodfellow, P. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-07-01
- Volume
- 27
- Issue
- 19
- Pages
- 3091-3096
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106361096
- Cited by
- 70
- References
- 9
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.